RenovoRx, Inc. (RNXT) Stock

Healthcare · Biotechnology · Member of Other US Stocks

RenovoRx, Inc. (RNXT) closed at USD 1.12 on 2026-10-14, a change of -0.9 % over the past year, with a market capitalization of USD 53.7M.

RenovoRx, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

RenovoRx, Inc. key figures

Previous close

USD 1.12 (2026-10-14)

1-year change

-0.9 %

Market cap

USD 53.7M

Enterprise value

USD 44.62M

P/E ratio (trailing)

-3.72

P/E ratio (forward)

-9.92

EPS (trailing)

-0.32

EPS (forward)

-0.12

PEG ratio

n/a

Price to book

5.98

Revenue growth

115.4 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.68

Employees

17

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About RenovoRx, Inc.

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for RenovoRx, Inc. and compare it with other stocks.